Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02491099
Title A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Yale University
Indications

endometrial serous adenocarcinoma

Therapies

Afatinib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.